Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SITC 2021 | Current status of immunotherapy for advanced melanoma

Omid Hamid • 12 Nov 2021
SITC 2021
Melanoma Skin Cancer Tebentafusp

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, gives an overview of current immunotherapeutic strategies for patients with advanced melanoma. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

More from Omid Hamid

1:54
C-144-01: lifileucel in mucosal melanoma pretreated with ICIs
Omid Hamid • 23 Oct 2023
2:31
The future of BiTEs and ImmTACs in melanoma and beyond
Omid Hamid • 23 Oct 2023
1:55
The benefits of tebentafusp in uveal melanoma
Omid Hamid • 23 Oct 2023
2:01
Elucidating biomarkers of response in the RELATIVITY-047 trial
Omid Hamid • 23 Oct 2023

Related Videos

1:27
Emerging trials in melanoma: SWOG S1801, OpACIN-neo and PRADO
Christoffer Gebhardt • 9 Apr 2024
2:12
Novel immunotherapeutic approaches to treat patients with melanoma
Christoffer Gebhardt • 9 Apr 2024
1:22
INTerpath-001: individualized neoantigen vaccines with pembrolizumab in melanoma
Christoffer Gebhardt • 9 Apr 2024
2:15
Reducing the need for sentinel node biopsies in cutaneous melanoma
Christoffer Gebhardt • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals